
Opinion|Videos|June 7, 2024
MM Treatment: CAR T-Cell Therapy Selection and Insurance Considerations
The panel discusses the utilization of CAR T-cell therapy for patients with multiple myeloma, highlighting treatment selection, sequencing, and insurance considerations.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How might you consider sequencing therapies for this patient? Please describe how you would approach treating this patient in your practice.
- What factors impact your decision?
- How do you incorporate patient preferences and quality of life considerations into the discussion when determining the sequencing of bispecifics and CAR T-cell therapy in R/R MM?
- Can BCMA-targeting bispecifics be used in patients who have received prior BCMA targeting CAR-T therapies?
- Might you consider a different target?
- Might your strategy differ if the patient had received ide-cel instead of cilta-cel?
Advertisement
Related to this article

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Giredestrant/Everolimus for ER+, HER2–, ESR1-Mutated Breast Cancer
2
Who Benefits Most From Perioperative Therapy in High-Risk Prostate Cancer?
3
Belzutifan Plus Lenvatinib Earns Positive CHMP Opinion in Advanced ccRCC
4
Rocbrutinib Plus R-CHOP Yields High Complete Response Rate in Non-GCB DLBCL
5


